TherapeuticsMD (NASDAQ:TXMD) released its earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.01), Briefing.com reports. The business had revenue of $4.13 million for the quarter, compared to analyst estimates of $4.66 million. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. TherapeuticsMD’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.12) earnings per share.
Shares of TherapeuticsMD (TXMD) traded down $0.27 during trading hours on Wednesday, hitting $5.31. 1,564,400 shares of the company’s stock were exchanged, compared to its average volume of 1,780,539. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30. The stock has a market cap of $1,207.51, a P/E ratio of -13.27 and a beta of 1.23.
A number of equities research analysts have issued reports on the stock. Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Friday, February 9th. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a report on Wednesday, December 20th. Deutsche Bank set a $9.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, December 20th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $31.00 target price on shares of TherapeuticsMD in a report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $14.50.
In other news, Director Tommy G. Thompson acquired 5,000 shares of the company’s stock in a transaction on Friday, December 8th. The shares were bought at an average cost of $6.21 per share, with a total value of $31,050.00. Following the transaction, the director now owns 3,555 shares in the company, valued at approximately $22,076.55. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 23.92% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/21/therapeuticsmd-txmd-issues-earnings-results.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.